Does the HPV Vaccine Prevent Throat Cancer?

For years, HPV vaccination was framed mainly around cervical and other anogenital cancers. A cohort study published in August 2026 makes the case that head and neck cancer should be part of the reason too. Researchers pulled deidentified records from 66 U.S. health systems, matched 716,630 vaccinated people aged 9 to 45 against the same number of unvaccinated people on age, sex, and existing conditions, and counted cancers over the next 5 to 13 years. The vaccinated group had 40 head and neck cancers. The controls had 130. The gap was widest for cancers of the oropharynx, where most HPV-driven head and neck cancers begin. That's the tonsils and the base of the tongue. Recorded risk there was roughly 90% lower, on very few cases.

Before this, the evidence stopped at infections

The argument for throat protection used to run through the virus rather than through tumors. A randomized trial of the bivalent vaccine in Costa Rica, a community-randomized trial in Finland, and U.S. survey data in young adults all found far less vaccine-type oral HPV among vaccinated people. That's the step you can actually measure. Persistent high-risk oral HPV is one step on the path to these cancers, and there's no oropharyngeal equivalent of a cervical precancer screen to check along the way. The FDA's head and neck indication for Gardasil 9 reflects that gap: it's an accelerated approval resting on the vaccine's effect against HPV-related anogenital disease, with the confirmatory trial on persistent oral HPV infection in men still outstanding.

What the study can't rule out

The cohort is huge. The cancers aren't. With counts this small, a handful of diagnoses either way moves the estimate, which is the perpetual problem with studying a cancer that's rare at these ages. The study also couldn't separate vaccination from what travels with it. If vaccinated people smoked less, drank less, or differed in sexual exposure, some of that gap belongs to those things rather than to the shot.

Two things make the signal harder to dismiss. The largest association landed on the oropharynx, the subsite most tightly tied to HPV, which is where you'd expect it if the vaccine were doing the work. And other record-based cohorts point the same direction: a global cohort found lower hypopharyngeal and laryngeal cancer rates after vaccination, though no significant drop in oral cavity cancer, and a 2026 cohort in males also reported lower head and neck cancer risk. Supportive, not definitive. Electronic-record cohorts carry healthy-user bias of their own. Then there's time. HPV-related oropharyngeal cancer usually surfaces long after the infection that caused it, so every vaccinated cohort so far is an early slice of a long story.

Age does most of the work

Prophylactic vaccines don't clear an infection you already have; they keep one from taking hold. That's why age at vaccination keeps coming out as the strongest predictor of benefit. In a nationwide Swedish register study, cervical cancer risk was about 80% lower among those vaccinated before 17, and closer to a third lower among those vaccinated at 17 or older. Protection itself doesn't seem to fade: Nordic follow-up in women out to 12 to 14 years found no waning against high-grade cervical lesions, and antibody responses held for most vaccine types. Durability isn't the weak point. Timing is.

So a child in the 9 to 12 window is the version of this decision with the most evidence behind it and the least ambiguity. If you're under 26 and not fully vaccinated, catch-up is the standard recommendation: for most people, two doses if you start before 15, three if you start at 15 or older.

If you're already past 26

The guidelines split here. The FDA label runs through age 45 and U.S. immunization guidance leaves 27 to 45 to individual decisions, while the American Cancer Society doesn't recommend it past 26 at all. The caution has a basis. Modeling of U.S. men suggests most causal oral HPV-16 infections are acquired by 26, so the average 40-year-old has less left to prevent. But an average isn't your exposure. A 2026 risk-based modeling analysis estimated that vaccinating the highest-risk 44% of heterosexual men aged 27 to 45 would prevent about 80% of the incident oral HPV-16 infections that would be prevented by vaccinating all men in that age band. If you have new or multiple partners ahead of you, you may be nearer that subset than the average. Against that is a licensed vaccine with a well-characterized safety record: injection-site pain is common, fainting can happen after vaccination, and CDC safety guidance and post-licensure surveillance have not found a confirmed pattern of serious events caused by it. Worth raising with a clinician on the merits rather than treating 26 as a wall.

Two things would sharpen the answer. The FDA-required confirmatory trial, testing whether the vaccine prevents persistent oral HPV infection in men aged 20 to 45, has an original projected completion date of September 30, 2026. And vaccinated cohorts need to age into the years when these cancers actually show up. Until then, a vaccine already given to prevent other HPV cancers now has cancer counts behind its throat-cancer claim, not just infection counts, and the counts point where the biology said they would.